Traws Pharma (TRAW) director granted 6,157 RSUs and 24,629 options

Rhea-AI Filing Summary

Traws Pharma, Inc. reported an insider equity award for director Jack E. Stover. On 12/12/2025, he received an award of 6,157 restricted stock units. According to the disclosure, these restricted stock units vest 100% on the first anniversary of the grant date, and each unit converts into one share of common stock.

On the same date, Stover was also granted a stock option for 24,629 shares of common stock at an exercise price of $2.33 per share. The option becomes exercisable on 12/12/2026 and expires on 12/12/2035. After these transactions, he beneficially owned 6,165 shares of common stock and 24,629 stock options, all held directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

STOVER JACK E

(Last) (First) (Middle)

C/O TRAWS PHARMA, INC

12 PENNS TRAIL

(Street)

NEWTOWN PA 18940

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Traws Pharma, Inc. [ TRAW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/12/2025		A		6,157(1)	A	$0	6,165	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to purchase)	$2.33	12/12/2025		A		24,629		12/12/2026(2)	12/12/2035	Common Stock	24,629	$0	24,629	D

Explanation of Responses:

1. Represents an award of restricted stock units that will vest 100% on the first anniversary of the grant date. Each restricted stock unit will convert into shares of common stock on a one-for-one basis.

2. The options vest 100% on the first anniversary of the grant date.

	/s/ Jack E. Stover	12/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Traws Pharma (TRAW) disclose for 12/12/2025?

Traws Pharma disclosed that director Jack E. Stover received an equity award on 12/12/2025, consisting of 6,157 restricted stock units and a stock option for 24,629 shares of common stock.

How many restricted stock units did the Traws Pharma director receive?

The director received an award of 6,157 restricted stock units. These units vest 100% on the first anniversary of the grant date, and each restricted stock unit converts into one share of common stock.

What are the key terms of the Traws Pharma director stock options?

The director was granted a stock option for 24,629 shares of common stock at an exercise price of $2.33 per share. The option vests 100% on 12/12/2026 and expires on 12/12/2035.

What is the director’s beneficial ownership in Traws Pharma after these grants?

Following the reported transactions, the director beneficially owned 6,165 shares of common stock and 24,629 stock options, all reported as held directly.

What roles does the reporting person hold at Traws Pharma (TRAW)?

The reporting person is identified as a director of Traws Pharma, Inc. on the ownership report.

How do the restricted stock units at Traws Pharma convert into shares?

Each restricted stock unit from this award will convert into one share of common stock upon vesting, which is scheduled to occur 100% on the first anniversary of the 12/12/2025 grant date.